BACKGROUND: Prostaglandin E(2) (PGE(2)) has well-established vasodilatory effects, whereas its effects on protein extravasation and its sensory effects are less clear. OBJECTIVE: Vasoactive effects of PGE(2) were correlated to its ability to evoke pain or itch in healthy volunteers and patients with atopic dermatitis (AD). METHODS: Intradermal microdialysis was used to apply PGE(2) (10(-8)-10(-4) M) via microdialysis capillaries in 8 patients and 8 controls. Large pore size membranes (3000 kd) enabled simultaneous analysis of protein extravasation. Itch and pain sensations were measured psychophysically, and superficial blood flow was measured by laser Doppler imaging. RESULTS: PGE(2) dose dependently provoked intense local vasodilation, weak pruritus, and pain, but no protein extravasation. No differences were found between patients with AD and controls for any parameter. CONCLUSION: We conclude that PGE(2) is a potent vasodilator and a weak pruritic agent in normal skin and in patients with AD, but does not provoke increased protein extravasation.
BACKGROUND:Prostaglandin E(2) (PGE(2)) has well-established vasodilatory effects, whereas its effects on protein extravasation and its sensory effects are less clear. OBJECTIVE: Vasoactive effects of PGE(2) were correlated to its ability to evoke pain or itch in healthy volunteers and patients with atopic dermatitis (AD). METHODS: Intradermal microdialysis was used to apply PGE(2) (10(-8)-10(-4) M) via microdialysis capillaries in 8 patients and 8 controls. Large pore size membranes (3000 kd) enabled simultaneous analysis of protein extravasation. Itch and pain sensations were measured psychophysically, and superficial blood flow was measured by laser Doppler imaging. RESULTS:PGE(2) dose dependently provoked intense local vasodilation, weak pruritus, and pain, but no protein extravasation. No differences were found between patients with AD and controls for any parameter. CONCLUSION: We conclude that PGE(2) is a potent vasodilator and a weak pruritic agent in normal skin and in patients with AD, but does not provoke increased protein extravasation.
Authors: Boyi Liu; Jasmine Escalera; Shrilatha Balakrishna; Lu Fan; Ana I Caceres; Eve Robinson; Aiwei Sui; M Craig McKay; M Allen McAlexander; Christina A Herrick; Sven E Jordt Journal: FASEB J Date: 2013-05-30 Impact factor: 5.191
Authors: Yoshie Umehara; Chanisa Kiatsurayanon; Juan Valentin Trujillo-Paez; Panjit Chieosilapatham; Ge Peng; Hainan Yue; Hai Le Thanh Nguyen; Pu Song; Ko Okumura; Hideoki Ogawa; François Niyonsaba Journal: Biomedicines Date: 2021-02-25
Authors: Maria Abreu; Marta Miranda; Mafalda Castro; Iolanda Fernandes; Renata Cabral; Ana Helena Santos; Sónia Fonseca; João Rodrigues; Magdalena Leander; Catarina Lau; Inês Freitas; Susana Coimbra; Alice Santos-Silva; Margarida Lima Journal: Adv Hematol Date: 2021-07-20